Market Overview

UPDATE: Wunderlich Reiterates Hold Rating, Raises PT on HeartWare International

Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking
HeartWare Q2 Loss Wider than Expected, Sales Top; Stock Up - Analyst Blog (Zacks)

In a report published Wednesday, Wunderlich Securities reiterated its Hold rating on HeartWare International (NASDAQ: HTWR), and raised its price target from $80.00 to $96.00.

Wunderlich noted, “Heartware (HTWR) announced very strong Q2 results after the close Tuesday. Revenues of $29.1mm increased 42% and were well above our high-end estimate of $25.3mm and Street consensus of $22.8mm. The loss of ($1.61) per share was much larger than our estimate of ($1.40), as R&D spending took another step up. Strong International performance (+76%) once again this quarter was exciting, as HTWR increasingly dominated the market outside the U.S. On the HVAD approval front, management remains hopeful of a near-term approval, but really offered no new insight into the process. We continue to assume a late 2012 approval. We reiterate our Hold rating, but are raising our price target on Heartware to $96 per share.”

HeartWare International closed on Tuesday at $86.88.

Latest Ratings for HTWR

Jul 2015Leerink SwannMaintainsOutperform
Jul 2015BarclaysMaintainsOverweight
Jul 2015JP MorganMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Wunderlich SecuritiesAnalyst Color Price Target Analyst Ratings


Related Articles (HTWR)

Get Benzinga's Newsletters